| (in millions, except per share data) | Quarter Ended September 30, 2026 | Full-Year Ended December 31, 2026 | |||||||||||||||||||||||||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
| Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense | $ | — | $ | 3.84 | $ | 3.88 | $ | 1,035 | $ | 13.87 | $ | 14.07 | |||||||||||||||||||||||
| Q3 2026 acquired IPR&D and milestones expense | 216 | (0.11) | (0.11) | 216 | (0.11) | (0.11) | |||||||||||||||||||||||||||||
Guidance including Q3 2026 acquired IPR&D and milestones expensea | $ | 216 | $ | 3.73 | $ | 3.77 | $ | 1,251 | $ | 13.76 | $ | 13.96 | |||||||||||||||||||||||